• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Baudax Bio Inc.

    11/15/23 5:25:01 PM ET
    $BXRX
    Misc Health and Biotechnology Services
    Health Care
    Get the next $BXRX alert in real time by email
    NT 10-Q 1 d882911dnt10q.htm NT 10-Q NT 10-Q

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 12b-25

     

     

    NOTIFICATION OF LATE FILING

     

    (CHECK ONE):      

    ☐  Form 10-K     ☐  Form 20-F     ☐  Form 11-K     ☒  Form 10-Q

    ☐  Form 10-D     ☐  Form N-CEN     ☐  Form N-CSR

     

     

    Commission File Number: 001-39101

      For Period Ended: September 30, 2023
      ☐  Transition Report on Form 10-K
      ☐  Transition Report on Form 20-F
      ☐  Transition Report on Form 11-K
      ☐  Transition Report on Form 10-Q
      ☐  Transition Report on Form N-SAR
      For the Transaction Period Ended:             

     

     

    READ INSTRUCTION (ON BACK PAGE) BEFORE PREPARING FORM. PLEASE PRINT OR TYPE.

    NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

          

     

    PART I — REGISTRANT INFORMATION

    Baudax Bio, Inc.

    Full Name of Registrant

    Former Name if Applicable

    490 Lapp Road

    Address of Principal Executive Office (Street and Number)

    Malvern, Pennsylvania, 19355

    City, State and Zip Code

    PART II — RULES 12b-25(b) AND (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    ☒      (a)   The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
    ☒      (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
    ☒      (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

    PART III — NARRATIVE

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

    Baudax Bio, Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 (the “10-Q”) by the prescribed due date due to ongoing analysis of the accounting treatment of current and past financing transactions by the company. In addition, our independent registered public accounting firm, KPMG LLP, needs to complete its quarterly review procedures after the Company completes the aforementioned tasks.

     

     

    PART IV — OTHER INFORMATION

     

    (1)          Name and telephone number of person to contact in regard to this notification
        Gerri Henwood          484              395-2440
        (Name)     (Area Code)     (Telephone Number)
    (2)     Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).    ☒  Yes    ☐  No
            
    (3)     Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?     ☐  Yes    ☒  No
        If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

    Baudax Bio, Inc.

    (Name of Registrant as Specified in Charter)

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 15, 2023     By:   /s/ Gerri Henwood
          Chief Executive Officer

     

     

     

    Get the next $BXRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BXRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Mcandrew Natalie

      3 - Baudax Bio, Inc. (0001780097) (Issuer)

      10/11/23 4:47:44 PM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 3: New insider Kim Yong Chan claimed ownership of 202,260 shares

      3 - Baudax Bio, Inc. (0001780097) (Issuer)

      7/13/23 4:21:37 PM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4: Henwood Geraldine bought $3,057 worth of shares (1,200 units at $2.55), increasing direct ownership by 98% to 2,427 units

      4 - Baudax Bio, Inc. (0001780097) (Issuer)

      12/19/22 8:09:42 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    SEC Filings

    See more
    • SEC Form 8-K filed by Baudax Bio Inc.

      8-K - Baudax Bio, Inc. (0001780097) (Filer)

      2/28/24 6:15:52 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 25-NSE filed by Baudax Bio Inc.

      25-NSE - Baudax Bio, Inc. (0001780097) (Subject)

      2/15/24 8:53:22 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Inc. filed SEC Form 8-K: Other Events

      8-K - Baudax Bio, Inc. (0001780097) (Filer)

      12/12/23 9:52:05 PM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Baudax Bio Announces Corporate Update

      Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024 MALVERN, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that following recent shareholder approval of corporate actions related to

      10/18/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

      MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is the Company's next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.

      9/28/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference

      MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that that the Company's management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13, 2023 in New York, NY. Gerri Henwood, President & Chief Executive Officer of Baudax Bio, will give a pre-recorded presentation highlighting the Company's cellular therapy progra

      9/7/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Financials

    Live finance-specific insights

    See more
    • Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

      MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on September 5, 2023. The shares of Series C Preferred Stock will be distri

      8/23/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Acquires TeraImmune, Inc.

      TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood to Serve as CEO of Combined Entity MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) --  Baudax Bio, Inc. (NASDAQ:BXRX) ("Baudax Bio" or the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, today announced the acquisition of TeraImmune, a privately held a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases. "This combination blends the world class scientific expertise of the TeraImmune team with

      6/30/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Announces Date of Reconvened Annual Meeting

      MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, recently announced that it has adjourned its Annual Meeting of Shareholders (the "Annual Meeting") without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum. The Annual Meeting will reconvene at 9:00 a.m. Eastern time on June 23, 2023 and will continue to be held virtually at www.virtualshareholdermeeting.com/BXRX2023. The record date for determining shareholders eligible to vote at the Special Meeting will remain the close of business

      6/6/23 9:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)

      SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)

      2/14/24 10:25:34 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)

      SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)

      2/6/24 11:12:01 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)

      SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)

      7/10/23 5:12:03 PM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Cosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational Growth

      Experienced financial executive will build on growth trajectory Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Rick Casten as Chief Financial Officer (CFO), bolstering its executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005044/en/Rick Casten, SVP and Chief Financial Officer, Cosette Pharmaceuticals (Photo: Business Wire) "I am excited to have Rick Casten join our team, with his more than two decades of experience in helping drive long term performance gains and financial growth. Rick joins Cosette at a pivotal inflection point

      7/6/22 8:15:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Strengthens Management Team with Appointment of Richard S. Casten as Chief Financial Officer

      MALVERN Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the appointment of Richard S. Casten, CPA, MBA as Chief Financial Officer. In this role, Mr. Casten will be responsible for leading and directing the financial activities of the Company. Mr. Casten brings to Baudax 25 years of diversified financial experience across pharmaceutical, Fortune 500 consumer products and public accounting. He replaces Ryan D. Lake, CPA who is transitioning to full time Chief Financial Officer for Recro. “I am delighted to welcome Richard to the Baudax team and believe his expertise and leadersh

      3/8/21 7:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care